ROIV - Roivant Sciences Ltd.
29.72
0.200 0.673%
Share volume: 9,137,320
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.31%
PREVIOUS CLOSE
CHG
CHG%
$29.52
0.20
0.01%
View ratios
| Fiscal Date | 06-30-2023 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
| Report Date | 08-14-2023 | 11-12-2024 | 02-10-2025 | 05-29-2025 | 11-10-2025 | 02-06-2026 | |
| Total revenue | 21.624 M | 4.475 M | 9.018 M | -39.572 M | 1.571 M | 1.999 M | |
| Cost of revenue | 4.214 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 17.410 M | 4.475 M | 9.018 M | -39.572 M | 1.571 M | 1.999 M | |
| -74.30% | 101.52% | -538.81% | 103.97% | 27.24% | |||
| Operating expenses | 281.323 M | 345.954 M | 283.140 M | 231.002 M | 307.693 M | 340.452 M | |
| Selling general and admin | 156.190 M | 202.881 M | 141.545 M | 98.465 M | 143.125 M | 175.072 M | |
| Research and development | 125.133 M | 143.073 M | 141.595 M | 132.537 M | 164.568 M | 165.380 M | |
| Total expenses | 285.537 M | 346.188 M | 283.399 M | 227.442 M | 307.804 M | 341.152 M | |
| 21.24% | -18.14% | -19.74% | 35.33% | 10.83% | |||
| Operating income | -263.913 M | -341.713 M | -274.381 M | -267.014 M | -306.233 M | -339.153 M | |
| Ebit | -263.913 M | -342.531 M | -275.050 M | -376.869 M | -332.886 M | -355.227 M | |
| Pretax income | -326.093 M | -224.383 M | -234.513 M | -292.839 M | -159.044 M | -290.369 M | |
| -31.19% | 4.51% | 24.87% | -45.69% | 82.57% | |||
| Income tax | 1.752 M | 12.458 M | -25.568 M | 48.629 M | 6.995 M | 23.332 M | |
| Net income basic | -291.816 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| 100.00% | |||||||
| Net income | -291.816 M | -279.924 M | 118.075 M | -252.375 M | -166.039 M | -313.701 M | |
| 4.08% | 142.18% | -313.74% | 34.21% | -88.93% |